1123: Natural History and Growth Characteristics of Oncocytomas Under Active Surveillance

2006 ◽  
Vol 175 (4S) ◽  
pp. 361-361
Author(s):  
Paul L. Crispen ◽  
Rosalia Viterbo ◽  
Richard E. Greenberg ◽  
David Y.T. Chen ◽  
Robert G. Uzzo
Keyword(s):  
Natural History ◽  
Active Surveillance ◽  
Growth Characteristics

A patient reported outcomes of treatments for desmoid tumors: An international natural history study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 11560-11560
Author(s):  
Danielle Braggio ◽  
Amanda Lucas ◽  
Lynne Hernandez ◽  
Kelly Mercier
Keyword(s):  
Natural History ◽  
Active Surveillance ◽  
Desmoid Tumor ◽  
Patient Reported Outcomes ◽  
The United States ◽  
Desmoid Tumors ◽  
Targeted Agents ◽  
Natural History Study ◽  
Systemic Treatments ◽  
Patient Reported

11560 Background: The Desmoid Tumor Research Foundation (DTRF) launched the natural history study (NHS) in 2017. At this time, there are no standard-of-care options for this rare sarcoma. The treatments, clinical descriptors, and the patient reported outcomes to pharmacologic agents are described here within. Methods: The web-based natural history study launched September 2017 in collaboration with the National Organization of Rare Disorders. It contains 15 surveys covering diagnostics, disease, treatment, care management, and quality of life. Treatment types included in the DTRF NHS were pharmacology, surgery, radiation, high-intensity focused ultrasound (HiFU), and active surveillance (watch and wait). Results: While surgery was once the primary intervention for desmoid tumor patients, the NHS participants reported that 47.6% had received active surveillance or no systemic treatment at diagnosis. This is most common for desmoid tumors located in abdominal wall (54/103; 52.4%). There were 87 reported cases of complete surgical resection, 38 incomplete resections, and 23 bowel resections. 9 amputations were reported; 8 participants reported recurrent disease following the removal of the limb. The non-surgical interventions, such as radiation and HiFU, were mostly described for participants with chest wall tumors (15 pts) and joints/extremities (10 pts). Many options for systemic therapies were described including sorafenib (44/284; 15.5%), sulindac (36/284; 12.7%), and anti-hormonal agents tamoxifen and toremifene (34/285; 10.9%) were described. Targeted agents, such as gamma secretase inhibitor, pazopanib, and sorafenib, were greater in the United States than the non-US country participants (21% vs 9%). Multiple lines of treatments were reported by 81 participants, surgery is greatest as the first intervention for all tumor locations (49/81, 60%), with the exception of those with head/neck tumors who received chemotherapy (6/11, 55%). Analysis has started to evaluate the efficacy of systemic treatments from these NHS data. The table describes the participant reported outcomes of anti-hormonal agents, chemotherapeutics, non-steroidal anti-inflammatories, and targeted agents. Both chemotherapies and targeted agents were reported to have 38.1% response rates from the participants with 34.3% and 23.8% of participants reported progressive disease on therapy, respectively. Conclusions: Desmoid tumor NHS study participants reported the use of many treatment modalities demonstrating a range of frequency of use by tumor location and efficacy. Data collection through the DTRF NHS is ongoing.[Table: see text]

Natural History, Role of Biopsy, and Active Surveillance of Renal Masses

Renal Cancer ◽  
2019 ◽  
pp. 133-157
Author(s):  
Benjamin T. Ristau ◽  
Anthony Corcoran ◽  
Marc C. Smaldone ◽  
Robert G. Uzzo ◽  
David Y. T. Chen
Keyword(s):  
Natural History ◽  
Active Surveillance ◽  
Renal Masses

Radial Scars and Complex Sclerosing Lesions of the Breast: Prevalence of Malignancy and Natural History Under Active Surveillance

2021 ◽  
Author(s):  
Elizabeth Kraft ◽  
Jessica N. Limberg ◽  
Katerina Dodelzon ◽  
Lisa A. Newman ◽  
Rache Simmons ◽  
...  
Keyword(s):  
Natural History ◽  
Active Surveillance

Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance

2018 ◽  
Vol 199 (3) ◽  
pp. 633-640 ◽  
Author(s):  
Thenappan Chandrasekar ◽  
Ardalan E. Ahmad ◽  
Kamel Fadaak ◽  
Kartik Jhaveri ◽  
Jaimin R. Bhatt ◽  
...  
Keyword(s):  
Natural History ◽  
Active Surveillance ◽  
Clinical Evidence ◽  
Renal Cysts ◽  
History Of

1096 The natural history of untreated prostate MRI lesions in an active surveillance prostate cancer population – 260 patient-years

2012 ◽  
Vol 11 (1) ◽  
pp. e1096-e1096a ◽  
Author(s):  
D.J. Stevens ◽  
C. Moore ◽  
H. Ahmed ◽  
C. Allen ◽  
A. Kirkham ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Natural History ◽  
Active Surveillance ◽  
Prostate Mri ◽  
History Of

scholarly journals PD50-02 NATURAL HISTORY OF PROSTATE CANCER ON ACTIVE SURVEILLANCE: STRATIFICATION BY MRI USING THE PRECISE RECOMMENDATIONS IN A UK COHORT OVER 11 YEARS

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Francesco Giganti* ◽  
Armando Stabile ◽  
Vasilis Stavrinides ◽  
Adam Retter ◽  
Clement Orczyk ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Natural History ◽  
Active Surveillance ◽  
History Of
Sign in / Sign up

Export Citation Format

Share Document